Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment
S De Flora, C Grassi, L Carati
European Respiratory Journal, doi:10.1183/09031936.97.10071535
N-acetylcysteine (NAC), an analogue and precursor of reduced glutathione, has been in clinical use for more than 30 yrs as a mucolytic drug. It has also been proposed for and/or used in the therapy and/or prevention of several respiratory diseases and of diseases involving an oxidative stress, in general. The objective of the present study was to evaluate the effect of long-term treatment with NAC on influenza and influenza-like episodes. A total of 262 subjects of both sexes (78% ≥65 yrs, and 62% suffering from nonrespiratory chronic degenerative diseases) were enrolled in a randomized, doubleblind trial involving 20 Italian Centres. They were randomized to receive either placebo or NAC tablets (600 mg) twice daily for 6 months. Patients suffering from chronic respiratory diseases were not eligible, to avoid possible confounding by an effect of NAC on respiratory symptoms. NAC treatment was well tolerated and resulted in a significant decrease in the frequency of influenza-like episodes, severity, and length of time confined to bed. Both local and systemic symptoms were sharply and significantly reduced in the NAC group. Frequency of seroconversion towards A/H 1 N 1 Singapore 6/86 influenza virus was similar in the two groups, but only 25% of virus-infected subjects under NAC treatment developed a symptomatic form, versus 79% in the placebo group. Evaluation of cell-mediated immunity showed a progressive, significant shift from anergy to normoergy following NAC treatment. Administration of N-acetylcysteine during the winter, thus, appears to provide a significant attenuation of influenza and influenza-like episodes, especially in elderly high-risk individuals. N-acetylcysteine did not prevent A/H 1 N 1 virus influenza infection but significantly reduced the incidence of clinically apparent disease.
Appendix This paper was written on behalf of the N-acetylcysteine in Immune System (NACIS) Group. The role of participating investigators and Italian institutions are listed below.
References
Ada, Jones, The immune response to influenza infection, Curr Top Microbiol Immunol
Anonymous, Influenza in the world, 1, Weekly Epidemiol Rec
Anonymous, Influenza in the world, 1, Weekly Epidemiol Rec
Anonymous, Influenza in the world, 1, Weekly Epidemiol Rec
Boman, Backer, Larsson, Melander, Wahlander, Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases, Eur J Respir Dis
Crystal, Bast, Oxidants and antioxidants: pathophysiologic determinants and therapeutic agents, Am J Med
Flanagan, Meredith, Use of N-acetylcysteine in clinical toxicology, Am J Med
Flora, Balansky, Bennicelli, Mechanisms of anticarcinogenesis: the example of N-acetylcysteine
Grassi, Morandini, A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis, Eur J Clin Pharmacol
Hennet, Ziltener, Frei, Peterhans, A kinetic study of immune mediators in the lungs of mice infected with influenza virus, J Immunol
Lennette, Schmidt, Diagnostic procedures for viral, rickettsial and chlamydial infections
Maeda, Akaike, Oxygen-free radicals as pathogenic molecules in viral diseases, Proc Soc Exp Biol Med
Meister, Long-term therapy with N-acetylcysteine controlled release tablets in patients with chronic bronchitis: a double-blind, placebo-controlled study (in German), Forum Prakt Allg Arzt
Meister, Metabolism and function of glutathione
Nain, Hinder, Gong, Tumor necrosis factor production of influenza A virus-infected macrophages and potentiating effect of lipopolysaccharides, J Immunol
Oddera, Silvestri, Sacco, Eftimiadi, Rossi, N-acetylcysteine enhances in vitro the intracellular killing of Staphylococcus aureus by human alveolar macrophages and blood polymorphonuclear leukocytes and partially protects phagocytes from self-killing, J Lab Clin Med
Ohman, Dahlgren, Follin, Lew, Stendahl, Nacetylcysteine enhances receptor-mediated phagocytosis by human neutrophils, Agents Action
Parr, Huitson, Oral N-acetylcysteine in chronic bronchitis, Br J Dis Chest
Peristeris, Clark, Gatti, N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production, Cell Immunol
Rasmussen, Glennow, Reduction in days of illness after long-term treatment with N-acetylcysteine controlled release tablets in patients with chronic bronchitis, Eur J Respir Dis
Riise, Larsson, Larsson, Jeanson, Andersson, The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy?, Eur Respir J
Rouse, Horohov, Immunosuppression in viral infections, Rev Infect Dis
Streightoff, Redmann, Delong, In vivo antiviral chemotherapy: anti-influenza action of compounds affecting mucous secretions, Antimicrob Agents Chemother
Study, Long-term acetylcysteine in chronic bronchitis: a double-blind, controlled study, Eur J Respir Dis
Ungheri, Pinasi, Sanson, N-acetylcysteine activity in influenza virus infection: pathogenetic role of xanthine oxidase and tumor necrosis factor (Abstract in Italian)
Verhaegen, Cock, Cree, Goldstain, Restoration of the impaired lymphocyte stimulation in old people by thymopoietin pentapeptide, J Clin Lab Immunol
Weksler, Age-associated changes in the immune response, J Am Geriatr Soc
{ 'indexed': { 'date-parts': [[2024, 10, 19]],
'date-time': '2024-10-19T04:12:07Z',
'timestamp': 1729311127587,
'version': '3.27.0'},
'reference-count': 0,
'publisher': 'European Respiratory Society (ERS)',
'issue': '7',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[1997, 7, 1]]},
'abstract': '<jats:p>N-acetylcysteine (NAC), an analogue and precursor of reduced glutathione, has been in '
'clinical use for more than 30 yrs as a mucolytic drug. It has also been proposed for and/or '
'used in the therapy and/or prevention of several respiratory diseases and of diseases '
'involving an oxidative stress, in general. The objective of the present study was to evaluate '
'the effect of long-term treatment with NAC on influenza and influenza-like episodes. A total '
'of 262 subjects of both sexes (78% > or = 65 yrs, and 62% suffering from nonrespiratory '
'chronic degenerative diseases) were enrolled in a randomized, double-blind trial involving 20 '
'Italian Centres. They were randomized to receive either placebo or NAC tablets (600 mg) twice '
'daily for 6 months. Patients suffering from chronic respiratory diseases were not eligible, '
'to avoid possible confounding by an effect of NAC on respiratory symptoms. NAC treatment was '
'well tolerated and resulted in a significant decrease in the frequency of influenza-like '
'episodes, severity, and length of time confined to bed. Both local and systemic symptoms were '
'sharply and significantly reduced in the NAC group. Frequency of seroconversion towards '
'A/H1N1 Singapore 6/86 influenza virus was similar in the two groups, but only 25% of '
'virus-infected subjects under NAC treatment developed a symptomatic form, versus 79% in the '
'placebo group. Evaluation of cell-mediated immunity showed a progressive, significant shift '
'from anergy to normoergy following NAC treatment. Administration of N-acetylcysteine during '
'the winter, thus, appears to provide a significant attenuation of influenza and '
'influenza-like episodes, especially in elderly high-risk individuals. N-acetylcysteine did '
'not prevent A/H1N1 virus influenza infection but significantly reduced the incidence of '
'clinically apparent disease.</jats:p>',
'DOI': '10.1183/09031936.97.10071535',
'type': 'journal-article',
'created': {'date-parts': [[2003, 4, 2]], 'date-time': '2003-04-02T20:35:41Z', 'timestamp': 1049315741000},
'page': '1535-1541',
'source': 'Crossref',
'is-referenced-by-count': 140,
'title': 'Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with '
'long-term N-acetylcysteine treatment',
'prefix': '10.1183',
'volume': '10',
'author': [ {'given': 'S', 'family': 'De Flora', 'sequence': 'first', 'affiliation': []},
{'given': 'C', 'family': 'Grassi', 'sequence': 'additional', 'affiliation': []},
{'given': 'L', 'family': 'Carati', 'sequence': 'additional', 'affiliation': []}],
'member': '81',
'published-online': {'date-parts': [[1997, 7, 1]]},
'container-title': 'European Respiratory Journal',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1183/09031936.97.10071535',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 10, 18]],
'date-time': '2024-10-18T13:43:53Z',
'timestamp': 1729259033000},
'score': 1,
'resource': {'primary': {'URL': 'http://publications.ersnet.org/lookup/doi/10.1183/09031936.97.10071535'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[1997, 7, 1]]},
'references-count': 0,
'journal-issue': { 'issue': '7',
'published-online': {'date-parts': [[1997, 7, 1]]},
'published-print': {'date-parts': [[1997, 7, 1]]}},
'alternative-id': ['10.1183/09031936.97.10071535'],
'URL': 'http://dx.doi.org/10.1183/09031936.97.10071535',
'relation': {},
'ISSN': ['0903-1936', '1399-3003'],
'subject': [],
'container-title-short': 'Eur Respir J',
'published': {'date-parts': [[1997, 7, 1]]}}
